UCLA Team Advances CRISPR Sickle Cell Therapy to Clinical Trial Stage
Source Summary
A UCLA-led research team has successfully scaled an experimental CRISPR-based blood stem cell therapy for sickle cell disease to meet the manufacturing standards and quality requirements necessary for clinical trials. The advancement demonstrates the transition of the gene-editing approach from laboratory development to a therapeutically viable treatment candidate.
Why it matters
This development represents a critical step in translating CRISPR gene-editing technology from research into a potential treatment for a serious genetic blood disorder affecting thousands of patients.
